Bill
Optimizing Research Progress Hope And New Cures Act or the ORPHAN Cures Act This bill modifies certain provisions under the Medicare Drug Price Negotiation Program with respect to orphan drugs. The Medicare Drug Price Negotiation Program…
Overview and Timeline are the same for every version. Text and Votes below change with the version you select.
Introduced in Senate — May 21, 2025
This Act may be cited as the “Optimizing Research Progress Hope And New Cures Act” or the “ORPHAN Cures Act”.
Section 1192(e) of the Social Security Act (42 U.S.C. 1320f–1(e)) is amended—
(1)
in paragraph (1), by adding at the end the following new subparagraph:
(C) Treatment of former orphan drugs
In calculating the amount of time that has elapsed with respect to the approval of a drug or licensure of a biological product under subparagraph (A)(ii) and subparagraph (B)(ii), respectively, the Secretary shall not take into account any period during which such drug or product was a drug described in paragraph (3)(A).
(2)
in paragraph (3)(A)—
(A)
by striking “only one rare disease or condition” and inserting “one or more rare diseases or conditions”; and
(B)
by striking “such disease or condition” and inserting “one or more rare diseases or conditions (as such term is defined in section 526(a)(2) of the Federal Food, Drug, and Cosmetic Act)”.